1Drossman DA.Psychosocial and psychophysiologic mechanisms in GI Ⅲ ness.In:Kirsner JB,ed.The growth of gastroenterologic knowledge in the 20th century.Philadelphia:Lea & Febiger; 1993.41～432.
2Whitehead WE,Palsson O,Jones KR.Systematic review of the comorbidity of irritable bowel syndrome with other disorders:what are the causes and implications? Gastroenterology,2002,122:1140～1156.
7O'Donnell LJ,Virjee J,Heaton KW.Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate.BMJ,1990,300:439～440.
8Longstreth GF,Drossman DA.Severe irritable bowel and functional abdominal pain syndromes:managing the patient and health care costs.Clin Gastroenterol Hepatol,2005,3:397～400.
9Chey WD,Chey WY,Heath AT,Dukes GE,Carter EG,Northcutt A,Ameen VZ.Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.Am J Gastroenterol,2004,99:2195～2203.
10Muller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Loffier H.Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.Aliment Pharmacol Ther,2005,21:11～20.
